{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:51:45Z","timestamp":1761897105631,"version":"build-2065373602"},"reference-count":205,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.clindermatol.2019.10.010","type":"journal-article","created":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T12:41:18Z","timestamp":1571920878000},"page":"235-249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Sclerodermalike syndromes: Great imitators"],"prefix":"10.1016","volume":"38","author":[{"given":"Cec\u00edlia","family":"Varj\u00fa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e1bor","family":"Kum\u00e1novics","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e1szl\u00f3","family":"Czirj\u00e1k","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Matucci-Cerinic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T\u00fcnde","family":"Minier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2019.10.010_bb0005","doi-asserted-by":"crossref","first-page":"137","DOI":"10.5301\/jsrd.5000249","article-title":"Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities","volume":"2","author":"Varga","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0010","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1136\/annrheumdis-2011-200742","article-title":"Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database","volume":"71","author":"Meier","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0015","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0020","first-page":"248","article-title":"Abnormal capillary patterns and systemic disease in scleroderma (progressive systemic sclerosis)","volume":"13","author":"Maricq","year":"1975","journal-title":"Bibl Anat"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0025","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/ard.2006.066340","article-title":"Survival and causes of death in 366 Hungarian patients with systemic sclerosis","volume":"67","author":"Czirjak","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0030","series-title":"Scleroderma and Pseudoscleroderma","first-page":"399","author":"Jablonska","year":"1975"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0035","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1085-5629(98)80064-3","article-title":"Scleroderma-like disorders","volume":"17","author":"Jablonska","year":"1998","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0040","series-title":"Systemic Sclerosis","first-page":"99","article-title":"Differential diagnosis of systemic sclerosis-like disorders","author":"Jablonska","year":"2004"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0045","series-title":"Systemic Sclerosis","first-page":"121","article-title":"Other fibrosing skin disorders","author":"Bolster","year":"2004"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0050","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.clindermatol.2005.01.019","article-title":"Scleroderma and pseudo-scleroderma: uncommon presentations","volume":"23","author":"Haustein","year":"2005","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0055","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11926-002-0006-0","article-title":"Scleroderma-like cutaneous syndromes","volume":"4","author":"Mori","year":"2002","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0060","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2174\/157339706778699850","article-title":"Clinical features of scleroderma-like disorders: a challenge for the rheumatologist","volume":"2","author":"Czirjak","year":"2006","journal-title":"Curr Rheumatol Rev"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0065","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.rdc.2007.11.001","article-title":"Scleroderma-like fibrosing disorders","volume":"34","author":"Boin","year":"2008","journal-title":"Rheum Dis Clin N Am"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0070","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jaad.2015.12.021","article-title":"Histopathologic characteristics of scleromyxedema: a study of a series of 34 cases","volume":"74","author":"Rongioletti","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0075","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3949\/ccjm.50.2.189","article-title":"Scleromyxedema associated with IgG lambda multiple myeloma","volume":"50","author":"Muldrow","year":"1983","journal-title":"Cleve Clin Q"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0080","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1023\/B:MEBR.0000043982.17294.9b","article-title":"Hepatitis C virus-associated extrahepatic manifestations: a review","volume":"19","author":"Sene","year":"2004","journal-title":"Metab Brain Dis"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0085","first-page":"221","article-title":"Fine-needle aspiration diagnosis of HIV-related conditions","volume":"4","author":"Hanks","year":"1996","journal-title":"Pathology (Phila)"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0090","first-page":"380","article-title":"Cutaneous mucinosis associated with lupus erythematosus","volume":"11","author":"Fowler","year":"1984","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0095","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.1365-4362.2001.01060.x","article-title":"Dermatomyositis and mucinosis","volume":"40","author":"del Pozo","year":"2001","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0100","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/rheumatology\/31.11.779","article-title":"Papular mucinosis (scleromyxoedema) complicating diffuse systemic sclerosis: clinical features and electron microscope observations","volume":"31","author":"Varga","year":"1992","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0105","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jaad.2013.01.007","article-title":"Scleromyxedema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients","volume":"69","author":"Rongioletti","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0110","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.1111\/ijd.13619","article-title":"Lichen myxedematosus: how to reach the accurate diagnosis","volume":"56","author":"Nofal","year":"2017","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0115","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/jdv.14466","article-title":"European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin. Part 2: scleromyxedema, scleredema and nephrogenic systemic fibrosis","volume":"31","author":"Knobler","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0120","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1002\/art.40530","article-title":"Monoclonal gammopathy-associated scleromyxedema presenting as leonine facies","volume":"70","author":"Park","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0125","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/ddg.12970","article-title":"Lichen myxedematosus: a case series focusing on clinical features, disease associations, and management","volume":"15","author":"Atci","year":"2017","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0130","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/MD.0b013e3181630835","article-title":"Scleromyxedema: a case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG)","volume":"87","author":"Blum","year":"2008","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0135","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1212\/WNL.53.5.1138","article-title":"Encephalopathy in scleromyxedema","volume":"53","author":"Johkura","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0140","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1212\/WNL.37.6.1054","article-title":"Monoclonal paraproteinemia with subacute encephalopathy, seizures, and scleromyxedema","volume":"37","author":"Reid","year":"1987","journal-title":"Neurology"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0145","first-page":"852","article-title":"Cardiomyopathy in scleromyxedema: report of a fatal case","volume":"20","author":"De Simone","year":"2010","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0150","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.lpm.2015.04.026","article-title":"Scleromyxedema (papular mucinosis) with dermato-neuro syndrome: a rare, potentially fatal complication","volume":"44","author":"Landais","year":"2015","journal-title":"Presse Med"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0155","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1067\/mjd.2001.111630","article-title":"Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema","volume":"44","author":"Rongioletti","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0160","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1001\/archderm.1966.01600190009002","article-title":"Scleromyxedema. A variant of lichen myxedematosus","volume":"93","author":"Rudner","year":"1966","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0165","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0190-9622(95)90007-1","article-title":"Scleromyxedema","volume":"33","author":"Dinneen","year":"1995","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0170","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1365-4362.1989.tb02437.x","article-title":"Scleromyxedema","volume":"28","author":"Harris","year":"1989","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0175","first-page":"1299","article-title":"Scleromyxedema with myopathy and hyperthyroidism","volume":"23","author":"Van Linthoudt","year":"1996","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0180","first-page":"85","article-title":"Scleromyxedema without paraproteinemia","volume":"124","author":"Pravata","year":"1989","journal-title":"G Ital Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0185","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/1523-1747.ep12543468","article-title":"Immunochemical analysis of the monoclonal paraprotein in scleromyxedema","volume":"70","author":"Kitamura","year":"1978","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0190","first-page":"920","article-title":"Papular mucinosis with IgG(K) M component","volume":"114","author":"Danby","year":"1976","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0195","first-page":"649","article-title":"Lichen myxedematosus and multiple myeloma type IgG\/kappa","volume":"31","author":"Krebs","year":"1980","journal-title":"Hautarzt"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0200","first-page":"1071","article-title":"Complete remission of scleromyxedema following autologous stem cell transplantation","volume":"137","author":"Feasel","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0205","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0190-9622(99)70383-X","article-title":"Scleromyxedema","volume":"41","author":"Bata-Csorgo","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0210","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0001-7310(05)73148-3","article-title":"Scleromyxedema: ultrastructural study","volume":"96","author":"Gomez-Diez","year":"2005","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0215","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000096914","article-title":"Scleromyxedema: successful treatment with thalidomide in two patients","volume":"214","author":"Amini-Adle","year":"2007","journal-title":"Dermatology"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0220","first-page":"109","article-title":"Significance of histopathologic analysis of skin lesions in scleromyxedema. Light microscopy, electron microscopy, immunohistochemistry and immunofluorescence microscopy","volume":"25","author":"Krajnc","year":"1998","journal-title":"Acta Med Austriaca"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0225","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00000372-200106000-00022","article-title":"Cutaneous mucinoses: microscopic criteria for diagnosis","volume":"23","author":"Rongioletti","year":"2001","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0230","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1067\/mjd.2001.111903","article-title":"Lichen myxedematosus with systemic involvement: clinical and autopsy findings","volume":"45","author":"Loggini","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0235","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00428-013-1424-2","article-title":"Specific lymph node involvement in scleromyxedema: a new diagnostic entity for hypermetabolic lymphadenopathy","volume":"462","author":"Delyon","year":"2013","journal-title":"Virchows Arch"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0240","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.trsl.2014.06.002","article-title":"Allogeneic stem cell transplantation for the treatment of refractory scleromyxedema","volume":"165","author":"Shayegi","year":"2015","journal-title":"Transl Res"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0245","doi-asserted-by":"crossref","first-page":"408","DOI":"10.2340\/00015555-1299","article-title":"Scleromyxoedema: clinical follow-up after successful treatment with high-dose immunoglobulins reveals different long-term outcomes","volume":"92","author":"Bidier","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0250","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/jdv.14244","article-title":"High-dose intravenous immunoglobulin therapy for scleromyxoedema: a prospective open-label clinical trial using an objective score of clinical evaluation system","volume":"31","author":"Guarneri","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0255","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.semarthrit.2007.10.015","article-title":"Intravenous gammaglobulin and thalidomide may be an effective therapeutic combination in refractory scleromyxedema: case report and discussion of the literature","volume":"38","author":"Efthimiou","year":"2008","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0260","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2165\/00128071-200809040-00008","article-title":"Transient efficacy of double high-dose chemotherapy and autologous peripheral stem cell transplantation, immunoglobulin, thalidomide, and bortezomib in the treatment of scleromyxedema","volume":"9","author":"Ataergin","year":"2008","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0265","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1093\/rheumatology\/ker209","article-title":"Thalidomide and dexamethasone followed by autologous stem cell transplantation for scleromyxoedema","volume":"50","author":"Bos","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0270","first-page":"319","article-title":"Discussion of scleredema adultorum","volume":"98","author":"Graff","year":"1968","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0275","doi-asserted-by":"crossref","first-page":"163","DOI":"10.5152\/eurjrheum.2015.0004","article-title":"Therapy resistant idiopathic scleredema: an underlying pathology not always present","volume":"2","author":"Kalfa","year":"2015","journal-title":"Eur J Rheumatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0280","first-page":"311","article-title":"Scleredema of Buschke in pediatric age group","volume":"15","author":"Nagi","year":"2005","journal-title":"J Coll Physicians Surg Pak"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0285","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3348\/kjr.2018.19.3.425","article-title":"Ultrasonographic findings of scleredema adultorum of Buschke involving the posterior neck","volume":"19","author":"Ha","year":"2018","journal-title":"Korean J Radiol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0290","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1111\/jdv.13272","article-title":"Scleredema. A multicentre study of characteristics, comorbidities, course and therapy in 44 patients","volume":"29","author":"Rongioletti","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0295","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jamadermatol.2013.8835","article-title":"Paraproteinemia-associated scleredema treated successfully with intravenous immunoglobulin","volume":"150","author":"Eastham","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0300","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2337\/diacare.6.2.189","article-title":"Scleredema diabeticorum: a common and distinct cutaneous manifestation of diabetes mellitus","volume":"6","author":"Cole","year":"1983","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0305","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1464-5491.1988.tb01030.x","article-title":"Scleroedema diabeticorum: a minor but often unrecognized complication of diabetes mellitus","volume":"5","author":"Sattar","year":"1988","journal-title":"Diabet Med"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0310","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.bbrc.2016.02.020","article-title":"AGEs trigger autophagy in diabetic skin tissues and fibroblasts","volume":"471","author":"Sun","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0315","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2340\/00015555-2846","article-title":"Treatment of scleroedema adultorum Buschke: a systematic review","volume":"98","author":"Miguel","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0320","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.2337\/dc17-1994","article-title":"Successful treatment of scleredema diabeticorum with tranilast: three case reports","volume":"41","author":"Sun","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0325","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.2337\/dc14-0730","article-title":"Improvement in clinical symptoms of scleredema diabeticorum by frequency-modulated electromagnetic neural stimulation: a case report","volume":"37","author":"Gandolfi","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0330","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/art.1780290212","article-title":"POEMS syndrome. Study of a patient with proteinuria, microangiopathic glomerulopathy, and renal enlargement","volume":"29","author":"Fam","year":"1986","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0335","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1365-2133.1987.tb04933.x","article-title":"The skin changes of POEMS syndrome","volume":"117","author":"Ishikawa","year":"1987","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0340","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/0002-9343(88)90277-X","article-title":"POEMS syndrome presenting as systemic sclerosis. Clinical and pathologic study of a case with microangiopathic glomerular lesions","volume":"84","author":"Viard","year":"1988","journal-title":"Am J Med"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0345","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1346-8138.2012.01609.x","article-title":"Skin sclerosis as a manifestation of POEMS syndrome","volume":"39","author":"Hasegawa","year":"2012","journal-title":"J Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0350","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00005792-198007000-00006","article-title":"Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: the POEMS syndrome. Report on two cases and a review of the literature","volume":"59","author":"Bardwick","year":"1980","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0355","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1182\/blood-2002-07-2299","article-title":"POEMS syndrome: definitions and long-term outcome","volume":"101","author":"Dispenzieri","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0360","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1001\/archinte.1982.00340190191032","article-title":"Rosen SW. POEMS syndrome: studies in a patient with an IgG-kappa M protein but no polyneuropathy","volume":"142","author":"Morrow","year":"1982","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0365","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.hoc.2017.09.012","article-title":"The peripheral neuropathies of POEMS syndrome and Castleman disease","volume":"32","author":"Mauermann","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0370","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1136\/jnnp-2018-318514","article-title":"Proposal of new clinical diagnostic criteria for POEMS syndrome","volume":"90","author":"Suichi","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0375","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/ajh.24171","article-title":"POEMS syndrome: update on diagnosis, risk-stratification, and management","volume":"90","author":"Dispenzieri","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0380","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/ajh.24802","article-title":"POEMS syndrome: 2017 update on diagnosis, risk stratification, and management","volume":"92","author":"Dispenzieri","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0385","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00415-018-9110-6","article-title":"POEMS syndrome: clinical update","volume":"266","author":"Brown","year":"2019","journal-title":"J Neurol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0390","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/j.1365-4632.2012.05648.x","article-title":"Cutaneous manifestations in patients with POEMS syndrome","volume":"52","author":"Miest","year":"2013","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0395","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/archdermatol.2010.100","article-title":"Skin manifestations and vascular endothelial growth factor levels in POEMS syndrome: impact of autologous hematopoietic stem cell transplantation","volume":"146","author":"Barete","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0400","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/0002-9343(94)90350-6","article-title":"POEMS syndrome: a study of 25 cases and a review of the literature. French Study Group on POEMS Syndrome","volume":"97","author":"Soubrier","year":"1994","journal-title":"Am J Med"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0405","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/postgradmedj-2018-135860","article-title":"Cutaneous manifestations as a clue to the diagnosis of POEMS syndrome","volume":"94","author":"Kumar","year":"2018","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0410","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1210\/jc.2018-01516","article-title":"Prevalence and course of endocrinopathy in POEMS syndrome","volume":"104","author":"Caimari","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0415","doi-asserted-by":"crossref","first-page":"836","DOI":"10.4065\/82.7.836","article-title":"Endocrinopathy in POEMS syndrome: the Mayo Clinic experience","volume":"82","author":"Gandhi","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0420","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/WCO.0000000000000610","article-title":"POEMS syndrome","volume":"31","author":"Keddie","year":"2018","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0425","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.ecl.2013.07.004","article-title":"Dermatologic manifestations of diabetes mellitus: a review","volume":"42","author":"Murphy-Chutorian","year":"2013","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0430","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s40257-017-0275-z","article-title":"Cutaneous manifestations of diabetes mellitus: a review","volume":"18","author":"Lima","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0435","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2337\/diacare.7.2.163","article-title":"Scleroderma-like changes in insulin-dependent diabetes mellitus: clinical and biochemical studies","volume":"7","author":"Buckingham","year":"1984","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0440","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1056\/NEJM198107233050403","article-title":"Limited joint mobility in childhood diabetes mellitus indicates increased risk for microvascular disease","volume":"305","author":"Rosenbloom","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0445","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/art.1780251112","article-title":"Digital sclerosis in children with insulin-dependent diabetes mellitus","volume":"25","author":"Seibold","year":"1982","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0450","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0140-6736(84)92114-7","article-title":"Fibrous disease of the breast, thyroiditis, and cheiroarthropathy in type I diabetes mellitus","volume":"1","author":"Soler","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0455","first-page":"201","article-title":"\u201cPraying hands\u201d of Albrecht Durer regarded by physicians","volume":"62","author":"Bednarska-Zytko","year":"1999","journal-title":"Arch Hist Filoz Med"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0460","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000342994","article-title":"Thyroid function and obesity","volume":"1","author":"Laurberg","year":"2012","journal-title":"Eur Thyroid J"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0465","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-4632.2007.03544.x","article-title":"Eosinophilic fasciitis: demographics, disease pattern and response to treatment: report of 12 cases and review of the literature","volume":"47","author":"Bischoff","year":"2008","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0470","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/RHU.0000000000000524","article-title":"Groove sign of eosinophilic fasciitis","volume":"23","author":"Fruchter","year":"2017","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0475","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0049-0172(88)90008-X","article-title":"Eosinophilic fasciitis: clinical spectrum and therapeutic response in 52 cases","volume":"17","author":"Lakhanpal","year":"1988","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0480","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s10067-006-0525-6","article-title":"Eosinophilic fasciitis: report of two cases and a systematic review of the literature dealing with clinical variables that predict outcome","volume":"26","author":"Endo","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0485","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/ajh.10475","article-title":"Acquired amegakaryocytic thrombocytopenia purpura and eosinophilic fasciitis: a long relapsing and remitting course","volume":"75","author":"Chaudhary","year":"2004","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0490","first-page":"1811","article-title":"In situ immunophenotype of the inflammatory infiltrate in eosinophilic fasciitis","volume":"30","author":"Toquet","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0495","first-page":"75","article-title":"Analysis of leukemia inhibitory factor, type 1 and type 2 cytokine production in patients with eosinophilic fasciitis","volume":"28","author":"Viallard","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0500","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1365-2133.2004.06062.x","article-title":"Serum levels of tissue inhibitor of metalloproteinase-1 and 2 in patients with eosinophilic fasciitis","volume":"151","author":"Jinnin","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0505","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/1346-8138.12563","article-title":"Serum levels of matrix metalloproteinase-13 in patients with eosinophilic fasciitis","volume":"41","author":"Asano","year":"2014","journal-title":"J Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0510","first-page":"569","article-title":"Diffuse fasciitis with hypergammaglobulinemia and eosinophilia: a new syndrome?","volume":"11","author":"Shulman","year":"1984","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0515","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2214\/ajr.184.1.01840169","article-title":"MRI for diagnosis and monitoring of patients with eosinophilic fasciitis","volume":"184","author":"Baumann","year":"2005","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0520","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.autrev.2014.01.019","article-title":"Diagnosis and classification of eosinophilic fasciitis","volume":"13","author":"Pinal-Fernandez","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0525","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/1346-8138.14160","article-title":"Diagnostic criteria, severity classification and guidelines of eosinophilic fasciitis","volume":"45","author":"Jinnin","year":"2018","journal-title":"J Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0530","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.0004-8461.2004.01331.x","article-title":"Ultrasound and magnetic resonance imaging features in a patient with eosinophilic fasciitis","volume":"48","author":"Chan","year":"2004","journal-title":"Australas Radiol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0535","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1093\/rheumatology\/kev290","article-title":"Ultrasound is a useful adjunct in diagnosis of eosinophilic fasciitis","volume":"54","author":"Mondal","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0540","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/qjmed\/hcq218","article-title":"Positron emission tomography in the diagnosis of eosinophilic fasciitis","volume":"104","author":"Cheriet","year":"2011","journal-title":"QJM"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0545","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/RLU.0000000000000260","article-title":"Usefulness of FDG PET\/CT in the diagnosis of eosinophilic fasciitis","volume":"39","author":"Kim","year":"2014","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0550","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/jamadermatol.2015.3648","article-title":"Epidemiology and treatment of eosinophilic fasciitis: an analysis of 63 patients from 3 tertiary care centers","volume":"152","author":"Wright","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0555","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/1756-185X.12499","article-title":"Eosinophilic fasciitis: clinical characteristics and response to methotrexate","volume":"18","author":"Berianu","year":"2015","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0560","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/rheumatology\/ker366","article-title":"Eosinophilic fasciitis (Shulman disease): new insights into the therapeutic management from a series of 34 patients","volume":"51","author":"Lebeaux","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0565","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1001\/jamadermatol.2016.2873","article-title":"High-dose intravenous pulse methotrexate in patients with eosinophilic fasciitis","volume":"152","author":"Mertens","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0570","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11926-017-0700-6","article-title":"Eosinophilic fasciitis: an updated review on diagnosis and treatment","volume":"19","author":"Mazori","year":"2017","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0575","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1046\/j.1365-2230.2002.00996.x","article-title":"Diagnosis of Werner syndrome by immunoblot analysis","volume":"27","author":"Shimizu","year":"2002","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0580","first-page":"760","article-title":"Werner\u2019s syndrome: from clinics to genetics","volume":"18","author":"Goto","year":"2000","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0585","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/00005792-196605000-00001","article-title":"Werner\u2019s syndrome a review of its symptomatology, natural history, pathologic features, genetics and relationship to the natural aging process","volume":"45","author":"Epstein","year":"1966","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0590","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0047-6374(97)00111-5","article-title":"Hierarchical deterioration of body systems in Werner\u2019s syndrome: implications for normal ageing","volume":"98","author":"Goto","year":"1997","journal-title":"Mech Ageing Dev"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0595","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0887-8994(96)00229-9","article-title":"Cockayne syndrome: review of 25 cases","volume":"15","author":"Ozdirim","year":"1996","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0600","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s13023-016-0543-7","article-title":"Ataxia telangiectasia: a review","volume":"11","author":"Rothblum-Oviatt","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0605","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0190-9622(87)70207-2","article-title":"Rothmund-Thomson syndrome. A case report, phototesting, and literature review","volume":"17","author":"Berg","year":"1987","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0610","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000085666","article-title":"Molecular cytogenetic insights into the ageing syndrome Hutchinson-Gilford Progeria (HGPS)","volume":"111","author":"Corso","year":"2005","journal-title":"Cytogenet Genome Res"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0615","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nature01629","article-title":"Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome","volume":"423","author":"Eriksson","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0620","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.exger.2007.07.004","article-title":"The neonatal progeroid syndrome (Wiedemann-Rautenstrauch): a model for the study of human aging?","volume":"42","author":"Arboleda","year":"2007","journal-title":"Exp Gerontol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0625","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/S0140-6736(85)92890-9","article-title":"Ageing in Down\u2019s syndrome","volume":"1","author":"Murdoch","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0630","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ymgme.2005.10.018","article-title":"Laminopathies: multisystem dystrophy syndromes","volume":"87","author":"Jacob","year":"2006","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0635","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/hmg\/ddh265","article-title":"Lamin A and ZMPSTE24 (FACE-1) defects cause nuclear disorganization and identify restrictive dermopathy as a lethal neonatal laminopathy","volume":"13","author":"Navarro","year":"2004","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0640","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/ajmg.1320240408","article-title":"Restrictive dermopathy: a newly recognized autosomal recessive skin dysplasia","volume":"24","author":"Witt","year":"1986","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0645","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1525-1470.2002.00029.x","article-title":"Restrictive dermopathy: a case report and a critical review of all hypotheses of its origin","volume":"19","author":"Nijsten","year":"2002","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0650","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1365-2133.1980.tb06595.x","article-title":"Familial acrogeria (Gottron)","volume":"103","author":"de Groot","year":"1980","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0655","first-page":"36","article-title":"Acrogeria of the Gottron type in a mother and son","volume":"10","author":"Blaszczyk","year":"2000","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0660","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1365-2133.2004.06113.x","article-title":"Acrogeria (Gottron type): a vascular disorder?","volume":"151","author":"Hashimoto","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0665","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0925-4439(96)00067-1","article-title":"Transforming growth factor-beta reverses deficient expression of type (I) collagen in cultured fibroblasts of a patient with metageria","volume":"1360","author":"Hunzelmann","year":"1997","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0670","first-page":"991","article-title":"Melorheostosis Leri: a case report","volume":"18","author":"Dillnhunt","year":"1936","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0675","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.pmrj.2016.07.530","article-title":"Melorheostosis: a retrospective clinical analysis of 24 patients at the Mayo Clinic","volume":"9","author":"Smith","year":"2017","journal-title":"PM R"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0680","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s003300000562","article-title":"Melorheostosis: a review of 23 cases","volume":"11","author":"Freyschmidt","year":"2001","journal-title":"Eur Radiol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0685","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/humu.9403","article-title":"Germline LEMD3 mutations are rare in sporadic patients with isolated melorheostosis","volume":"27","author":"Hellemans","year":"2006","journal-title":"Hum Mutat"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0690","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.foot.2017.02.004","article-title":"Melorheostosis-foot and ankle perspective","volume":"31","author":"Dhillon","year":"2017","journal-title":"Foot (Edinb)"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0695","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.kjms.2011.11.009","article-title":"Surgical treatment of melorheostosis: report of two cases","volume":"28","author":"Chou","year":"2012","journal-title":"Kaohsiung J Med Sci"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0700","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00256-002-0576-y","article-title":"Atypical form of active melorheostosis and its treatment with bisphosphonate","volume":"31","author":"Don\u00e1th","year":"2002","journal-title":"Skelet Radiol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0705","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.04.2009.1757","article-title":"Melorheostosis and its treatment with intravenous zoledronic acid","volume":"2010","author":"Hollick","year":"2010","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0710","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s13256-018-1820-y","article-title":"Clinical improvement in a patient with monostotic melorheostosis after treatment with denosumab: a case report","volume":"12","author":"Byberg","year":"2018","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0715","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1076\/jhin.12.1.44.13788","article-title":"Asbjorn Folling and the discovery of phenylketonuria","volume":"12","author":"Christ","year":"2003","journal-title":"J Hist Neurosci"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0720","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1610-0387.2009.07137.x","article-title":"Disorders of pigmentation","volume":"8","author":"Fistarol","year":"2010","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0725","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.autrev.2007.12.004","article-title":"Scleroderma-like disorders","volume":"7","author":"Foti","year":"2008","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0730","first-page":"32","article-title":"The Guthrie test. Midwifery basics","volume":"5","author":"Baston","year":"2002","journal-title":"Pract Midwife"},{"year":"2018","series-title":"Phenylketonuria","author":"Stone","key":"10.1016\/j.clindermatol.2019.10.010_bb0735"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0740","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.0736-8046.2004.21422.x","article-title":"Stiff skin syndrome is highly heterogeneous, and congenital fascial dystrophy is its distinct subset","volume":"21","author":"Jablonska","year":"2004","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0745","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/jdv.12657","article-title":"Four new cases of stiff skin syndrome with unusual presentations","volume":"30","author":"Deng","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0750","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/rheumatology\/kep118","article-title":"Stiff skin syndrome: evidence for an inflammation-independent fibrosis?","volume":"48","author":"Guiducci","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0755","first-page":"181","article-title":"Stiff skin syndrome and myeloma successfully treated with autologous haematopoietic stem cell transplantation (HSCT)","volume":"31","author":"Bandinelli","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0760","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/j.1365-4632.2012.05478.x","article-title":"Stiff skin syndrome in a newborn infant","volume":"52","author":"Halverstam","year":"2013","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0765","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1016\/j.jaad.2016.05.047","article-title":"Segmental stiff skin syndrome (SSS): two additional cases with a positive response to mycophenolate mofetil and physical therapy","volume":"75","author":"Kurtzman","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0770","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0140-6736(74)92515-X","article-title":"Letter: Parana hard-skin syndrome: study of seven families","volume":"1","author":"Cat","year":"1974","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0775","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s10067-009-1178-z","article-title":"Stiff skin syndrome versus scleroderma: a report of two cases","volume":"28","author":"Azevedo","year":"2009","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0780","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s12016-017-8625-4","article-title":"Cutaneous manifestations of scleroderma and scleroderma-like disorders: a comprehensive review","volume":"53","author":"Ferreli","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0785","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/MD.0b013e3181d50928","article-title":"Familial and sporadic porphyria cutanea tarda: clinical and biochemical features and risk factors in 152 patients","volume":"89","author":"Munoz-Santos","year":"2010","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0790","first-page":"441","article-title":"Porphyria cutanea tarda","volume":"56","author":"Ghosh","year":"2008","journal-title":"J Assoc Physicians India"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0795","doi-asserted-by":"crossref","first-page":"361","DOI":"10.17219\/acem\/58955","article-title":"Clinical, biochemical and molecular characteristics of the main types of porphyria","volume":"25","author":"Szlendak","year":"2016","journal-title":"Adv Clin Exp Med"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0800","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.ejim.2014.02.009","article-title":"Sporadic porphyria cutanea tarda: treatment with chloroquine decreases hyperglycemia and reduces development of metabolic syndrome","volume":"25","author":"Gonzalez-Estrada","year":"2014","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0805","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1684\/ejd.2012.1758","article-title":"Successful treatment of refractory blisters in porphyria cutanea tarda with topical pimecrolimus combined with oral hydroxychloroquine: an alternative to phlebotomy in patients with renal insufficiency and anemia","volume":"22","author":"Chou","year":"2012","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0810","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.cgh.2012.08.038","article-title":"Low-dose hydroxychloroquine is as effective as phlebotomy in treatment of patients with porphyria cutanea tarda","volume":"10","author":"Singal","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0815","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0378-4274(99)00220-9","article-title":"Autoimmune diseases associated with drugs, chemicals and environmental factors","volume":"112-113","author":"D\u2019Cruz","year":"2000","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0820","series-title":"Case Studies in Systemic Sclerosis","first-page":"73","article-title":"A 35-year-old man with diffuse scleroderma and chemical exposure","author":"Czirjak","year":"2011"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0825","first-page":"533","article-title":"Clinical findings in 61 patients with progressive systemic sclerosis","volume":"69","author":"Czirjak","year":"1989","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0830","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/PL00011216","article-title":"Exposure to solvents in female patients with scleroderma","volume":"21","author":"Czirjak","year":"2002","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0835","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/00000372-200110000-00001","article-title":"Nephrogenic fibrosing dermopathy","volume":"23","author":"Cowper","year":"2001","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0840","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/00002281-200311000-00017","article-title":"Nephrogenic fibrosing dermopathy: the first 6 years","volume":"15","author":"Cowper","year":"2003","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0845","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1001\/archderm.139.7.928","article-title":"What nephrogenic fibrosing dermopathy might be","volume":"139","author":"LeBoit","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0850","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/archderm.139.7.903","article-title":"Nephrogenic fibrosing dermopathy with systemic involvement","volume":"139","author":"Ting","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0855","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/01.bor.0000245725.94887.8d","article-title":"Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy)","volume":"18","author":"Galan","year":"2006","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0860","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1525-139X.2007.00406.x","article-title":"Patient characteristics and risk factors for nephrogenic systemic fibrosis following gadolinium exposure","volume":"21","author":"Grobner","year":"2008","journal-title":"Semin Dial"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0865","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/ndt\/gfk062","article-title":"Gadolinium\u2014a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?","volume":"21","author":"Grobner","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0870","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1093\/ndt\/gfl592","article-title":"Dermal and extra-dermal manifestations of gadolinium-triggered nephrogenic fibrosing dermopathy","volume":"21","author":"Stollberger","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0875","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.carj.2017.11.002","article-title":"Gadolinium-based contrast agents in kidney disease: comprehensive review and clinical practice guideline issued by the Canadian Association of Radiologists","volume":"69","author":"Schieda","year":"2018","journal-title":"Can Assoc Radiol J"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0880","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/jmri.25625","article-title":"Gadolinium-based contrast agents: a comprehensive risk assessment","volume":"46","author":"Fraum","year":"2017","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0885","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.jaad.2010.08.041","article-title":"Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations","volume":"65","author":"Girardi","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0890","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s13244-015-0420-2","article-title":"Revisiting the risks of MRI with gadolinium based contrast agents-review of literature and guidelines","volume":"6","author":"Khawaja","year":"2015","journal-title":"Insights Imaging"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0895","doi-asserted-by":"crossref","first-page":"426","DOI":"10.5414\/CNP73426","article-title":"The German registry for nephrogenic systemic fibrosis: findings from 23 patients","volume":"73","author":"Becker","year":"2010","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0900","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1136\/ard.2010.134791","article-title":"Gadolinium and systemic fibrosis: guilt by association","volume":"69","author":"Kay","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0905","first-page":"296","article-title":"Immunohistologic and ultrastructural study of the sclerotic skin in chronic graft-versus-host disease in man","volume":"115","author":"Janin-Mercier","year":"1984","journal-title":"Am J Pathol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0910","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/sj.bmt.1703386","article-title":"Progressive interstitial fibrosis of the lung in sclerodermoid chronic graft-versus-host disease","volume":"29","author":"Wolff","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0915","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1046\/j.1468-3083.2003.00606.x","article-title":"Bullous scleroderma-like changes in chronic graft-versus-host disease","volume":"17","author":"Moreno","year":"2003","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0920","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1002\/art.1780220815","article-title":"A syndrome resembling progressive systemic sclerosis after bone marrow transplantation. A model for scleroderma?","volume":"22","author":"Furst","year":"1979","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0925","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0140-6736(77)90772-3","article-title":"Scleroderma-like graft-versus-host disease as late consequence of bone-marrow grafting","volume":"2","author":"Siimes","year":"1977","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0930","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0935","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.beha.2008.02.008","article-title":"Diagnosis and manifestations of chronic graft-versus-host disease","volume":"21","author":"Filipovich","year":"2008","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0940","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jaad.2005.06.015","article-title":"Lichen sclerosus and eosinophilic fasciitis as manifestations of chronic graft-versus-host disease: expanding the sclerodermoid spectrum","volume":"53","author":"Schaffer","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0945","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0950","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-4362.1981.tb04329.x","article-title":"Cutaneous manifestations of graft-versus-host disease","volume":"20","author":"Saurat","year":"1981","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0955","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.bbmt.2014.12.031","article-title":"NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group report","volume":"21","author":"Shulman","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0960","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1097\/01.bor.0000144760.37777.fa","article-title":"Autoantibodies in systemic sclerosis and fibrosing syndromes: clinical indications and relevance","volume":"16","author":"Cepeda","year":"2004","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0965","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1182\/blood-2014-08-551994","article-title":"How we treat chronic graft-versus-host disease","volume":"125","author":"Flowers","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0970","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1365-2133.2007.08415.x","article-title":"U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease","volume":"158","author":"Scarisbrick","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0975","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines5040060","article-title":"A critical appraisal of extracorporeal photopheresis as a treatment modality for acute and chronic graft-versus-host disease","volume":"5","author":"Rafei","year":"2017","journal-title":"Biomedicines"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0980","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbmt.2010.05.011","article-title":"Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease","volume":"17","author":"Wolff","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0985","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.bbmt.2009.04.003","article-title":"Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis","volume":"15","author":"Kharfan-Dabaja","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0990","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1182\/blood-2009-02-204156","article-title":"Imatinib for refractory chronic graft-versus-host disease with fibrotic features","volume":"114","author":"Olivieri","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb0995","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.bbmt.2015.03.006","article-title":"Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease","volume":"21","author":"Baird","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb1000","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/s41409-017-0081-5","article-title":"Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease","volume":"53","author":"Khoury","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb1005","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1038\/leu.2015.212","article-title":"Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey","volume":"29","author":"Zeiser","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb1010","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.bbmt.2018.09.003","article-title":"Ruxolitinib as salvage therapy for chronic graft-versus-host disease","volume":"25","author":"Modi","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb1015","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2230.1994.tb01126.x","article-title":"Scleroderma and the carcinoid syndrome","volume":"19","author":"Ratnavel","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb1020","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/ced.12046","article-title":"Cutaneous scleroderma and malignant carcinoid syndrome","volume":"38","author":"Becher","year":"2013","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.010_bb1025","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1186\/1756-0500-7-571","article-title":"Scleredema-an uncommon cause of swelling in a child-a case report and review of the literature","volume":"7","author":"Shrestha","year":"2014","journal-title":"BMC Res Notes"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X19301865?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X19301865?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:16:07Z","timestamp":1760033767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X19301865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":205,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0738081X19301865"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2019.10.010","relation":{},"ISSN":["0738-081X"],"issn-type":[{"type":"print","value":"0738-081X"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sclerodermalike syndromes: Great imitators","name":"articletitle","label":"Article Title"},{"value":"Clinics in Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clindermatol.2019.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}